CHAIR
:
SPEAKER
(S):
Gail Cassell, PhD, DSc (hon), Vice President, Scientific Affairs and Distinguished Lilly Research Scholar for Infectious Diseases, Eli Lilly & Company
Christopher Earl, PhD, President & CEO, BIO Ventures for Global Health (BVGH), USA
Luis Salicrup, PhD, Senior Advisor for International Technology Transfer, National Institutes of Health, Office of Technology Transfer (NIH-OTT)
Gerald Siuta, PhD, Director Business Development, Global Alliance for TB Drug Development
Description
Biotechnology can create highly targeted approaches for preventing or treating infectious and chronic diseases. This session will highlight concrete R&D steps taken by partnerships involving industry, nonprofit organizations and government to accelerate the development of new therapeutics and diagnostics to fight diseases affecting needy populations worldwide.
Objectives:
Illustrate the opportunity for the biotech industry to have an impact on neglected diseases.
Discuss the need for partnerships between the public and private sectors to drive innovation.
Show the increasing flow of funds into this work and the continuing need to augment the pipeline with innovative products.